| |
Newsroom /
Medical
/
Medical
/
Liver Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Liver Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
The Liver Cirrhosis Therapeutics Market is Forecast to Show Modest Growth Until 2017
Hyderabad,
AP,
India
(prbd.net)
15/02/2011
GlobalData estimated the global liver cirrhosis market to be valued at $1.56 billion in 2010. It is expected to grow to $2.03 billion with a Compound Annual Growth Rate (CAGR) of 3.8% by 2017. This growth is primarily attributed to the increasing prevalence of the disease due to increase in alcoholic liver disease, nonalcoholic steatohepatitis (NASH) and the large group of patients who were originally infected with hepatitis virus, who will be entering their third decade of chronic liver infection.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Liver-Cirrhosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
GlobalData analyzed that the available treatment options are moderately successful in meeting the market demand. Liver cirrhosis treatment is a supportive treatment and hence the drugs aim at treating the complications of the disease. Thus treatment of cirrhosis includes preventing further damage to the liver, treating the complications of cirrhosis and preventing liver cancer or detecting it early. There are drugs available for each of the complications and these off-label drugs have good safety and efficacy profiles. It is because of this that the unmet need is low even though there are no approved drugs for liver cirrhosis. However, there is still scope available for new entrants with new disease-modifying mechanisms of action, increased clinical performance and high safety profiles. There is scope for new entrants which will aim at reversal of the disease and increasing the survival rates because liver cirrhosis is a leading cause of morbidity and mortality worldwide.
GlobalData analyzed that there are seven molecules in various stages of the pipeline. Lucassin, AST-120, HPN-100, and Copegus plus Pegasys are some of the late stage pipeline molecules. The market is dominated by off-label products and these molecules target the complications for which there are presently no approved therapies. These emerging therapies are likely to intensify the competition in the liver cirrhosis market as they have to compete with the generics.
GlobalData, the industry analysis specialist’s new report, “Liver Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global liver cirrhosis therapeutics market. The report identifies the key trends shaping and driving the global liver cirrhosis therapeutics market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global liver cirrhosis therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Liver-Cirrhosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|